| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/02/2025 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 22/01/2025 | 22:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/11/2024 | 13:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/11/2024 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/11/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 17/10/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 16/10/2024 | 22:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 11/10/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 14/09/2024 | 09:10 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 10/09/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 09/09/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/08/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 29/05/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 17/05/2024 | 00:52 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 14/05/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 24/04/2024 | 22:01 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 17/04/2024 | 02:01 | GlobeNewswire Inc. | Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 10/04/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistanc | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 09/04/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces $130 Million Private Placement Financing | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 28/03/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 05/03/2024 | 22:30 | GlobeNewswire Inc. | Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/03/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 27/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/02/2024 | 21:40 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 08/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 06/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 12/01/2024 | 22:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/01/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 18/12/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/12/2023 | 22:35 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
